This project will enable Marshfield to continue to participate in National Cancer Institute approved clinical research as well as cancer control studies in cancer patients offered through the following research bases: 1) Eastern Cooperative Oncology Group (ECOG), 2) National Surgical Adjuvant Breast and Bowel Project (NSABP), 3) Children's Cancer Study Group (CCSG), and 4) Fox Chase Cancer Center (FCCC). This contract will be administratively and physically conducted by the Marshfield Medical Research Foundation. This program will also enable Marshfield CCOP physicians and personnel to attend research base organizational meetings. Due to the increased accession of cancer patients at the Marshfield medical complex, it is anticipated that there will be expansion of both clinical research and interventional cancer control activities. Maintenance of excellent quality research programs, by continued participation in various quality assurance programs, is a goal of the Marshfield CCOP. Ongoing communication with the National Cancer Institute and research base scientists, along with community oncologists, helps transfer the latest research findings for the benefit of Marshfield community cancer patients. With planned expansion of interventional cancer control activities, there will be increased effort to screen and detect early cancers for improving cure rates and to prevent exposure to carcinogenic agents resulting in ultimate lowering of cancer incidence. The ultimate goal of this program is to attempt to achieve the Year 2000 goal of the National Cancer Institute, that is, to reduce the mortality of cancer patients to fifty percent.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035412-09
Application #
3557740
Study Section
Special Emphasis Panel (SRC (A))
Project Start
1983-09-01
Project End
1993-05-31
Budget Start
1992-06-01
Budget End
1993-05-31
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Marshfield Clinic Research Foundation
Department
Type
DUNS #
074776030
City
Marshfield
State
WI
Country
United States
Zip Code
54449
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75
Cleeland, Charles S; Zhao, Fengmin; Chang, Victor T et al. (2013) The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer 119:4333-40
Rowe, J M; Andersen, J W; Mazza, J J et al. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86:457-62
Kay, N E; Oken, M M; Mazza, J J et al. (1988) Evidence for tumor reduction in refractory or relapsed B-CLL patients with infusional interleukin-2. Nouv Rev Fr Hematol 30:475-8
Krause, D; Lesiak, K; Imai, J et al. (1986) Activation of 2-5A-dependent RNase by analogs of 2-5A (5'-O-triphosphoryladenylyl(2'----5')adenylyl(2'----5')adenosine ) using 2',5'-tetraadenylate (core)-cellulose. J Biol Chem 261:6836-9